Clinical Trial Update: Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety and immune responses of HIV-1 vaccines M3 and M4 in HIV-infected adults, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• M3
• M4

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2022-08-09